Agios 制药

最新新闻

• 评级变动
  Goldman Sachs Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Raises Target Price to $32
  \u5e02\u573a\u8d44\u8baf · 2026/6/2
• 评级变动
  BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $46
  \u5e02\u573a\u8d44\u8baf · 2026/7/7
• 评级变动
  A Quick Look at Today's Ratings for Agios Pharmaceuticals(AGIO.US), With a Forecast Between $36 to $54
  \u5e02\u573a\u8d44\u8baf · 2026/6/16
• Truist Financial Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• Truist Financial Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Announces Target Price $39
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• 评级变动
  H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $54
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• 评级变动
  A Quick Look at Today's Ratings for Agios Pharmaceuticals(AGIO.US), With a Forecast Between $41 to $54
  \u5e02\u573a\u8d44\u8baf · 2026/7/8
• 评级变动
  BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $40
  \u5e02\u573a\u8d44\u8baf · 2026/6/12
• A Quick Look at Today's Ratings for Agios Pharmaceuticals(AGIO.US), With a Forecast Between $39 to $55
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• 评级变动
  H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/6/2
• 评级变动
  BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $46
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Cuts Target Price to $52
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  H.C. Wainwright Remains a Buy on Agios Pharma (AGIO)
  TipRanks · 2026/7/13
• 评级变动
  J.P. Morgan Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Maintains Target Price $31
  \u5e02\u573a\u8d44\u8baf · 2026/6/11
• BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $50
  \u5e02\u573a\u8d44\u8baf · 2026/9/21
• 公司公告
  Agios Pharmaceuticals: Agios Pharmaceuticals, Inc. - Flex Position Consolidation Option Symbol: 1AGIO
  OCC · 2022/4/28
• 评级变动
  J.P. Morgan Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Announces Target Price $31
  \u5e02\u573a\u8d44\u8baf · 2026/6/11
• TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 评级变动
  Truist Financial Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Announces Target Price $36
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• 评级变动
  H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $54
  \u5e02\u573a\u8d44\u8baf · 2026/6/15

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。